Description: Companies are looking to modernize their FP&A processes and functions to deliver actionable insights, particularly in light of regulatory changes such as IFRS 17, LDTI, and PBR. New key performance indicators (KPIs) are emerging and FP&A function needs to evolve and adapt to these new paradigms, being a key function in monitoring the company's financial performance. Discover perspectives from filers under different bases: statutory, GAAP and IFRS and come learn how to elevate and enrich data, models, processes, and technology amidst changes to regulatory reporting. You'll also cover key considerations for the optimal design and interaction model between Finance, Actuarial, and other departments.

Description: Long Duration Targeting Improvement's (LDTI's) roll-forward disclosure requirements include line items for the impact of actual variances from expected experience (A/E) for both net premiums and benefits. These aggregate A/E amounts provide some insight into how actual experience is emerging relative to expectations, but they do not provide insight into either the drivers of the deviations or their significance.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Have you wondered: - As a U.S. insurer, should I try to understand the implication of International Financial Reporting Standard 17 (IFRS 17) on global insurers? - As a pricing actuary, do I need to learn about the financial evolution brought about by IFRS 17 and Long Duration Targeted Improvements (LDTI)? - As my organization's CFO, I have invested in the arduous implementation of the new standards. How do I get the best return on my investment?If the answer to any of the above is 'Yes,' then this session is for you!

Description: IUL continues to be the strongest selling UL product. Companies have great profit/pricing expectations, but are those results being achieved? Learn about potential areas of underperformance for IUL including behavior related issues, hedging inefficiency, and mortality issues. The session will also discuss ways to monitor these risks and discuss different means to address potential issues of underperformance in hedging, pricing and in force earnings.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: With IFRS 17 effective this year, come learn about the performance management capabilities provided by IFRS 17 with traditional analysis under IFRS4, and with LDTI under USGAAP. You will begin with an introduction to the IFRS 17 landscape post implementation, followed by a comparison of profit measurement and earning analysis key performance indicators (KPIs) pre- and post-IFRS 17, and ends with an exploration of the common philosophy of earning recognition between LDTI and IFRS 17 beyond the calculation differences.

Description: Forward looking insurers are reimagining their businesses with key strategic aims around how they engage with their customers and how they make and implement decisions. Industry experts will present a maturity framework for assessing your progress with specific case studies for how to advance in the areas of Management Information, New Business, and Inforce Management.

Description: The National Association of Insurance Commissioners (NAIC) is working on changes to the health risk-based capital (RBC) formula. Will your RBC ratio improve or deteriorate under the new formula? And what can you do about it?

Description: The panel will discuss several product challenges including modeling hybrid/combo long-term care products, modeling benefit options that are difficult to model using deterministic methods, modeling current situs of care versus original situs of care, monitoring assumptions, streamlining experience studies within the Long-duration Targeted Improvements (LDTI) framework, and model decision making with limited credible data. The panel will then move into solutions observed to address some of the aforementioned challenges and the future of long-term care modelling